Novartis bets big on gene therapy with $8.7 billion AveXis deal

ZURICH (Reuters) - Novartis is moving further into gene therapy with a $8.7 billion deal for AveXis that gives the Swiss drugmaker a rare-disease treatment seen reaping billions in sales and bolsters its technology base.

Novartis bets big on gene therapy with $8.7 billion AveXis deal
Read More


Bagikan Berita Ini